Last reviewed · How we verify
Beta-blocker, ACE-inhibitor
At a glance
| Generic name | Beta-blocker, ACE-inhibitor |
|---|---|
| Sponsor | University of Aarhus |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease (PHASE1, PHASE2)
- Venous Congestion And Cognitive Dysfunction After Cardiac Surgery
- Baroreflex Activation Therapy for Heart Failure (NA)
- Exercise Rehabilitation for Cardiorenal Syndrome in HFrEF Patients (NA)
- Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction
- Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure (NA)
- Short-Term Effects of Antihypertensive Drugs on Postural Balance and Fall Risk (NA)
- RAFT - Pace &Ablate (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beta-blocker, ACE-inhibitor CI brief — competitive landscape report
- Beta-blocker, ACE-inhibitor updates RSS · CI watch RSS
- University of Aarhus portfolio CI